Myriad Genetics (MYGN) Stock Price

Myriad Genetics Price

NASDAQ·CLOSED
2.86USD-2.51 (-61.00 %)
Market closed

Revenue has compounded at 11.0% per year over the past 19 years to 824.50 M USD. Earnings per share have declined at 17.1% per year over the last 11 years. Myriad Genetics's net margin stands at -44.4%, down from -3.9% several years earlier. Analysts set a median price target of 7.14 USD, implying 149.7% above the current price. Of 18 analysts, 3 rate the stock a buy — an overall Hold consensus.

Myriad Genetics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Myriad Genetics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Myriad Genetics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Myriad Genetics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Myriad Genetics Stock Price History
DateMyriad Genetics Price
7/31/20262.86 USD
7/30/20265.37 USD
7/29/20265.18 USD
7/27/20265.66 USD
7/23/20265.70 USD
7/22/20265.66 USD
7/21/20265.91 USD
7/20/20265.92 USD
7/17/20266.18 USD
7/16/20266.19 USD
7/15/20266.31 USD
7/14/20266.04 USD
7/13/20265.97 USD
7/10/20265.83 USD
7/9/20266.10 USD
7/8/20265.73 USD
7/7/20265.86 USD
7/6/20265.86 USD
7/2/20265.99 USD
7/1/20266.00 USD
6/30/20265.71 USD
6/29/20265.85 USD
6/26/20265.88 USD
6/25/20265.43 USD
6/24/20265.22 USD
6/23/20264.63 USD
6/22/20264.47 USD
6/18/20264.49 USD
6/17/20264.41 USD
6/16/20264.38 USD
6/15/20264.32 USD
6/12/20264.40 USD
6/11/20264.47 USD
6/10/20264.74 USD
6/9/20264.54 USD
6/8/20264.39 USD
6/5/20264.57 USD
6/4/20264.69 USD
6/3/20264.40 USD
6/2/20264.31 USD
6/1/20264.28 USD
5/29/20263.97 USD
5/28/20264.22 USD
5/27/20263.93 USD
5/26/20263.85 USD
5/22/20263.82 USD
5/21/20263.91 USD
5/20/20263.81 USD
5/19/20263.55 USD
5/18/20263.65 USD
5/15/20263.58 USD
5/14/20263.62 USD
5/13/20263.73 USD
5/12/20264.07 USD
5/11/20264.21 USD
5/8/20264.29 USD
5/7/20264.09 USD
5/6/20264.11 USD
5/5/20265.03 USD
5/4/20264.94 USD
5/1/20264.80 USD
4/30/20264.75 USD
4/29/20264.68 USD
4/28/20264.84 USD
4/27/20264.83 USD
4/24/20264.78 USD
4/23/20264.81 USD
4/22/20265.08 USD
4/21/20264.99 USD
4/20/20265.14 USD
4/17/20265.08 USD
4/16/20265.00 USD
4/15/20265.19 USD
4/14/20264.91 USD
4/13/20264.59 USD
4/10/20264.35 USD
4/9/20264.44 USD
4/8/20264.77 USD
4/7/20264.74 USD
4/6/20264.67 USD
4/2/20264.75 USD
4/1/20264.59 USD
3/31/20264.50 USD
3/30/20264.36 USD
3/27/20264.28 USD
3/26/20264.62 USD
3/25/20264.68 USD
3/24/20264.61 USD
3/23/20264.66 USD
3/20/20264.58 USD
3/19/20264.75 USD
3/18/20264.64 USD
3/17/20264.78 USD
3/16/20264.59 USD
3/13/20264.66 USD
3/12/20264.85 USD
3/11/20265.06 USD
3/10/20265.12 USD
3/9/20264.81 USD
3/6/20265.15 USD
3/5/20265.13 USD
3/4/20265.28 USD
3/3/20265.29 USD
3/2/20265.01 USD
2/27/20264.61 USD
2/26/20264.86 USD
2/25/20264.78 USD
2/24/20264.43 USD
2/23/20264.38 USD
2/20/20264.29 USD
2/19/20264.38 USD
2/18/20264.37 USD
2/17/20264.50 USD
2/13/20264.49 USD
2/12/20264.53 USD
2/11/20264.85 USD
2/10/20265.08 USD
2/9/20265.07 USD
2/6/20265.12 USD
2/5/20265.10 USD
2/4/20265.30 USD
2/3/20265.34 USD
2/2/20265.47 USD
1/30/20265.62 USD
1/29/20265.54 USD
1/28/20265.72 USD
1/27/20265.92 USD
1/26/20265.81 USD
1/23/20265.87 USD
1/22/20266.06 USD
1/21/20265.84 USD
1/20/20265.68 USD
1/16/20265.92 USD
1/15/20266.04 USD
1/14/20266.11 USD
1/13/20266.20 USD
1/12/20266.57 USD
1/9/20266.58 USD
1/8/20266.56 USD
1/7/20266.63 USD
1/6/20266.52 USD
1/5/20266.14 USD
1/2/20266.14 USD
12/31/20256.15 USD
12/30/20256.17 USD
12/29/20256.31 USD
12/26/20256.48 USD
12/24/20256.55 USD
12/23/20256.56 USD
12/22/20256.76 USD
12/19/20256.55 USD
12/18/20256.70 USD
12/17/20256.95 USD
12/16/20256.88 USD
12/15/20256.99 USD
12/12/20257.21 USD
12/11/20257.30 USD
12/10/20257.23 USD
12/9/20257.35 USD
12/8/20257.07 USD
12/5/20257.09 USD
12/4/20257.33 USD
12/3/20257.33 USD
12/2/20257.02 USD
12/1/20257.06 USD
11/28/20257.63 USD
11/26/20257.60 USD
11/25/20257.91 USD
11/24/20257.73 USD
11/21/20257.38 USD
11/20/20256.90 USD
11/19/20256.44 USD
11/18/20256.63 USD
11/17/20256.66 USD
11/14/20256.71 USD
11/13/20256.35 USD
11/12/20256.54 USD
11/11/20256.68 USD
11/10/20256.48 USD
11/7/20256.30 USD
11/6/20256.33 USD
11/5/20256.58 USD
11/4/20256.46 USD
11/3/20258.18 USD
10/31/20258.04 USD
10/30/20257.95 USD
10/29/20257.91 USD
10/28/20258.13 USD
10/27/20258.10 USD
10/24/20258.15 USD
10/23/20258.05 USD
10/22/20257.86 USD
10/21/20258.06 USD
10/20/20257.90 USD
10/17/20257.80 USD
10/16/20258.08 USD
10/15/20258.10 USD
10/14/20257.80 USD
10/13/20257.84 USD
10/10/20257.50 USD
10/9/20257.74 USD
10/8/20257.64 USD
10/7/20257.53 USD
10/6/20257.99 USD
10/3/20258.06 USD
10/2/20257.56 USD
10/1/20257.73 USD
9/30/20257.23 USD
9/29/20257.24 USD
9/26/20257.70 USD
9/25/20257.76 USD
9/24/20257.72 USD
9/23/20257.70 USD
9/22/20257.84 USD
9/19/20257.77 USD
9/18/20257.68 USD
9/17/20257.40 USD
9/16/20257.50 USD
9/15/20257.31 USD
9/12/20257.24 USD
9/11/20257.68 USD
9/10/20256.90 USD
9/9/20256.97 USD
9/8/20256.91 USD
9/5/20256.61 USD
9/4/20256.79 USD
9/3/20256.80 USD
9/2/20256.90 USD
8/29/20256.37 USD
8/28/20256.22 USD
8/27/20255.93 USD
8/26/20255.81 USD
8/25/20255.89 USD
8/22/20256.02 USD
8/21/20255.83 USD
8/20/20255.53 USD
8/19/20255.51 USD
8/18/20255.71 USD
8/15/20255.71 USD
8/14/20255.89 USD
8/13/20255.87 USD
8/12/20256.03 USD
8/11/20256.19 USD
8/8/20256.32 USD
8/7/20256.10 USD
8/6/20255.67 USD
8/5/20253.87 USD
8/4/20253.98 USD
Access this data via the Eulerpool API
Get Free API Key

Myriad Genetics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
753.20 M USD
-259.30 M USD
-263.30 M USD
Jan 1, 2024
837.60 M USD
-122.40 M USD
-127.30 M USD
Jan 1, 2025
824.50 M USD
-67.80 M USD
-365.90 M USD
Jan 1, 2026 (e)
863.56 M USD
-212.52 M USD
5.67 M USD
Jan 1, 2027 (e)
915.77 M USD
-225.37 M USD
13.99 M USD
Jan 1, 2028 (e)
970.10 M USD
-238.74 M USD
25.16 M USD
Jan 1, 2029 (e)
1.08 B USD
-264.65 M USD
52.78 M USD
Jan 1, 2030 (e)
1.10 B USD
-269.75 M USD
59.26 M USD

Myriad Genetics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 1, 2026, 11:32 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.720.750.770.770.850.560.690.680.750.840.820.860.920.971.081.10
-7.074.152.390.1310.23-34.5523.88-1.7411.0611.16-1.554.736.036.0110.821.95
79.5379.1577.8277.0776.3867.8671.4570.2168.6669.8969.9069.9069.9069.9069.9069.90
575.00596.00600.00595.00650.00378.00493.00476.00517.00585.00576.00603.26639.61678.06751.46766.14
134.00166.0049.00118.0023.00-194.00-51.00-140.00-259.00-122.00-67.00-212.00-225.00-238.00-264.00-269.00
18.5322.056.3615.282.70-34.83-7.39-20.65-34.40-14.58-8.13-24.57-24.59-24.54-24.56-24.54
80.00125.0021.00131.004.00-223.00-27.00-112.00-263.00-127.00-365.005.0013.0025.0052.0059.00
-54.5556.25-83.20523.81-96.95-5,675.00-87.89314.81134.82-51.71187.40-101.37160.0092.31108.0013.46
73.8068.3071.9076.5074.4075.3079.9081.5086.1091.1093.3093.3093.3093.3093.3093.30
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Myriad Genetics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Myriad Genetics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Myriad Genetics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Myriad Genetics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Myriad Genetics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Myriad Genetics stock margins

The Myriad Genetics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Myriad Genetics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Myriad Genetics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
71.39 %
-7.41 %
-3.94 %
Jan 1, 2022
70.22 %
-20.64 %
-16.51 %
Jan 1, 2023
68.64 %
-34.43 %
-34.96 %
Jan 1, 2024
69.89 %
-14.61 %
-15.20 %
Jan 1, 2025
69.93 %
-8.22 %
-44.38 %
Jan 1, 2026 (e)
69.93 %
-24.61 %
0.66 %
Jan 1, 2027 (e)
69.93 %
-24.61 %
1.53 %
Jan 1, 2028 (e)
69.93 %
-24.61 %
2.59 %

Myriad Genetics Stock Revenue, EBIT, Earnings per Share

The Myriad Genetics earnings per share therefore indicates how much revenue Myriad Genetics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
8.64 USD
-0.64 USD
-0.34 USD
Jan 1, 2022
8.32 USD
-1.72 USD
-1.37 USD
Jan 1, 2023
8.75 USD
-3.01 USD
-3.06 USD
Jan 1, 2024
9.19 USD
-1.34 USD
-1.40 USD
Jan 1, 2025
8.84 USD
-0.73 USD
-3.92 USD
Jan 1, 2026 (e)
9.33 USD
-2.28 USD
0.06 USD
Jan 1, 2027 (e)
9.89 USD
-2.42 USD
0.15 USD
Jan 1, 2028 (e)
10.48 USD
-2.56 USD
0.27 USD

Myriad Genetics business model & stock analysis

Myriad Genetics Inc. is a biotechnology company specializing in the research of cancer and genetic analysis technologies. The company was founded in 1991 by Mark Skolnick and has since become a global leader in personalized medicine and diagnostics. It is headquartered in Salt Lake City, Utah, USA, and employs over 2,400 employees worldwide.

Myriad Genetics SWOT Analysis

Strengths

1. Strong Intellectual Property Portfolio: Myriad Genetics Inc possesses a significant number of patents and licenses, providing a competitive advantage in the genetic testing industry.

2. Broad Range of Products and Services: The company offers a comprehensive suite of genetic tests and related services, catering to different medical specialties and patient needs.

3. Established Market Presence: Myriad Genetics Inc has achieved a reputable position in the market, with a long history of delivering reliable genetic testing solutions and gaining the trust of healthcare professionals.

Weaknesses

1. Dependence on Few Key Products: Myriad Genetics Inc relies heavily on a limited number of flagship products, which exposes the company to the risk of market fluctuations and potential loss of market share.

2. Regulatory Challenges: The genetic testing industry is tightly regulated, and changing regulations can impact Myriad Genetics Inc's ability to operate or require costly compliance measures.

3. Limited International Expansion: The company's presence is primarily concentrated in the United States, limiting its potential growth opportunities in international markets.

Opportunities

1. Growing Demand for Genetic Testing: The increasing awareness and importance of personalized medicine present a significant opportunity for Myriad Genetics Inc to expand its customer base and introduce new testing solutions.

2. Advances in Genetic Research: Technological advancements and ongoing research in genetics offer the potential for the development of innovative tests and services, allowing the company to stay ahead of competitors.

3. Strategic Partnerships: Collaborating with pharmaceutical companies, healthcare organizations, and research institutions can provide Myriad Genetics Inc with access to new markets, resources, and expertise.

Threats

1. Competition: The genetic testing industry is becoming increasingly competitive, with the entry of new players and the presence of established companies offering similar services, posing a threat to Myriad Genetics Inc's market share.

2. Reimbursement Challenges: Changes in healthcare policies and reimbursement rates can impact the company's profitability and restrict patient access to genetic testing services.

3. Ethical and Legal Concerns: The handling and interpretation of genetic data raise ethical and privacy concerns, requiring Myriad Genetics Inc to continually address legal and regulatory challenges.

Myriad Genetics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Myriad Genetics Employees
Details
Date
Myriad Genetics Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Myriad Genetics Segments

Myriad Genetics Revenue by Segment (1/5)

  • 3 Years

  • 5 Years

  • Max

Molecular diagnostic testing
Molecular diagnostic hereditary cancer testing
Molecular diagnostic GeneSight testing
Molecular diagnostic Prenatal testing
Pharmaceutical and clinical services
Molecular diagnostic Vectra testing
Molecular diagnostic Prolaris testing
Molecular diagnostic other testing
Molecular diagnostic EndoPredict testing
Details
Date
Testing Revenue
Molecular diagnostic testing
Molecular diagnostic revenues
Molecular diagnostic hereditary cancer testing
Hereditary Cancer
Prenatal
Pharmacogenomics
Mental Health
Tumor Profiling
Molecular diagnostic GeneSight testing
Molecular diagnostic Prenatal testing
Pharmaceutical and clinical services
Molecular diagnostic Vectra testing
Molecular diagnostic Prolaris testing
Molecular diagnostic other testing
Molecular diagnostic EndoPredict testing
Other revenue
Autoimmune
Jan 1, 2013
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2014
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2015
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
719.30 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
53.30 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
479.70 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
112.60 M USD
104.90 M USD
0.00 USD
48.30 M USD
25.50 M USD
8.00 M USD
10.40 M USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Myriad Genetics Revenue by Segment (2/5)

  • 3 Years

  • 5 Years

  • Max

Molecular diagnostic testing
Pharmaceutical and clinical services
Details
Date
Molecular diagnostic testing
Pharmaceutical and clinical services
Jan 1, 2013
0.00 USD
0.00 USD
Jan 1, 2014
0.00 USD
0.00 USD
Jan 1, 2015
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD
Jan 1, 2019
789.40 M USD
61.70 M USD
Jan 1, 2020
586.90 M USD
51.70 M USD

Myriad Genetics Revenue by Segment (3/5)

  • 3 Years

  • 5 Years

  • Max

Molecular diagnostic hereditary cancer testing
Molecular diagnostic GeneSight testing
Molecular diagnostic Prenatal testing
Molecular diagnostic Vectra testing
Molecular diagnostic Prolaris testing
Molecular diagnostic other testing
Molecular diagnostic EndoPredict testing
Details
Date
Molecular diagnostic hereditary cancer testing
Molecular diagnostic GeneSight testing
Molecular diagnostic Prenatal testing
Molecular diagnostic Vectra testing
Molecular diagnostic Prolaris testing
Molecular diagnostic other testing
Molecular diagnostic EndoPredict testing
Jan 1, 2013
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2014
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2015
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
347.40 M USD
74.10 M USD
76.70 M USD
39.10 M USD
24.70 M USD
14.40 M USD
10.50 M USD

Myriad Genetics Revenue by Segment (4/5)

  • 3 Years

  • 5 Years

  • Max

Other
Details
Date
Other
Jan 1, 2013
0.00 USD
Jan 1, 2014
0.00 USD
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
45.10 M USD

Myriad Genetics Revenue by Segment (5/5)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Molecular Diagnostics
Diagnostics
Other
Other Segments
Companion Diagnostics
Pharmaceutical And Clinical Services
Details
Date
Molecular Diagnostics
Diagnostics
Other
Other Segments
Companion Diagnostics
Pharmaceutical And Clinical Services
Jan 1, 2013
582.39 M USD
0.00 USD
0.00 USD
0.00 USD
30.77 M USD
0.00 USD
Jan 1, 2014
748.20 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
30.02 M USD
Jan 1, 2015
0.00 USD
695.50 M USD
0.00 USD
27.60 M USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
705.70 M USD
0.00 USD
48.10 M USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
722.10 M USD
49.30 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
719.30 M USD
53.30 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
789.40 M USD
61.70 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
593.50 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Myriad Genetics Revenue by Region

  • 3 Years

  • Max

United States
International
RoW
Details
Date
United States
International
RoW
Jan 1, 2021
603.70 M USD
86.90 M USD
0.00 USD
Jan 1, 2022
591.50 M USD
86.90 M USD
0.00 USD
Jan 1, 2023
671.70 M USD
81.50 M USD
0.00 USD
Jan 1, 2024
769.50 M USD
68.10 M USD
0.00 USD
Jan 1, 2025
768.00 M USD
0.00 USD
56.50 M USD

Myriad Genetics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Myriad Genetics historical P/E ratio, EBIT multiple, and P/S ratio

Myriad Genetics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Myriad Genetics shares outstanding

The number of shares of Myriad Genetics was 93.3 M in 2025. This indicates how many shares Myriad Genetics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
79.90 M Stocks
Jan 1, 2022
81.50 M Stocks
Jan 1, 2023
86.10 M Stocks
Jan 1, 2024
91.10 M Stocks
Jan 1, 2025
93.30 M Stocks
Jan 1, 2026 (e)
93.30 M Stocks
Jan 1, 2027 (e)
93.30 M Stocks
Jan 1, 2028 (e)
93.30 M Stocks

Myriad Genetics stock splits

In Myriad Genetics's history, there have been no stock splits.

Current Myriad Genetics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
16.67 % (3)
Hold
50.00 % (9)
Sell
33.33 % (6)
12M Price Target
7.14
Last Price
2.86
Currency
USD
12M Return Potential
149.65 %
LTM Return
0 %

Myriad Genetics Analyst Rating Actions

DateFirmActionRating
7/31/2026
TD Cowen
TD Cowen
MaintainedHold
5/6/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight
5/6/2026
TD Cowen
TD Cowen
MaintainedHold
2/24/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight
2/24/2026
UBS
UBS
MaintainedNeutral
11/11/2025
Piper Sandler
Piper Sandler
MaintainedOverweight
11/5/2025
Wells Fargo
Wells Fargo
MaintainedEqual Weight
11/4/2025
UBS
UBS
MaintainedNeutral
11/4/2025
TD Cowen
TD Cowen
MaintainedHold
5/21/2025
Scotiabank
Scotiabank
DowngradeSector OutperformSector Perform

Myriad Genetics Earnings Calls

2025

Myriad Genetics Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
7/30/2026-0.06USD210.15 MUSD2026 Q2
5/4/2026-0.07USD206.43 MUSD2026 Q1
4/30/2026-0.07USD206.43 MUSD2026 Q1
3/3/2026-0.02USD211.13 MUSD2025 Q4
2/23/2026-0.02USD211.13 MUSD2025 Q4
1/15/2026-0.02USD210.96 MUSD2025 Q4
5/1/2024-0.03USD199.38 MUSD2024 Q1
2/26/20240.02USD197.99 MUSD2023 Q4
11/15/2022-0.06USD178.38 MUSD2023 Q3
11/1/2022-0.06USD172.65 MUSD2022 Q3

EESG©

Eulerpool ESG Scorecard© for the Myriad Genetics stock

41/100
36
Environment
51
Social
37
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees61
Percentage of women in management—
Percentage of Asian employees8
Share of Asian management—
Percentage of Hispanic/Latino employees7
Hispano/Latino Management share—
Percentage of Black employees4
Black Management Share—
Percentage of white employees77
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Myriad Genetics shareholder structure

% Name
14.75276%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
8.76610%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
7.23559%
Millennium Management LLC
Millennium Management LLC
6.44338%
State Street Investment Management (US)
State Street Investment Management (US)
5.33592%
Glenview Capital Management, LLC
Glenview Capital Management, LLC
4.86522%
D. E. Shaw & Co., L.P.
D. E. Shaw & Co., L.P.
...

Myriad Genetics Beneficial Ownership Filings (SEC 13D/G)

Free Float
93.0%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
18.40%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
11.46%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
11.00%
Baillie Gifford & Co (Scottish partnership)
Baillie Gifford & Co (Scottish partnership)
SEC ↗
8.50%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
6.30%
Capital Research Global Investors **
Capital Research Global Investors **
SEC ↗
5.70%
Southeastern Asset Management, Inc.
Southeastern Asset Management, Inc.
SEC ↗
5.60%
Integrated Core Strategies (US) LLC
Integrated Core Strategies (US) LLC
SEC ↗
5.31%
LARRY ROBBINS
LARRY ROBBINS
SEC ↗
5.30%
GLENVIEW CAPITAL MANAGEMENT, LLC
GLENVIEW CAPITAL MANAGEMENT, LLC
SEC ↗
5.28%
Sterling Capital Management LLC
Sterling Capital Management LLC
SEC ↗

Myriad Genetics Executives and Management Board

SR

Mr. Samraat Raha

(52)

President, Chief Executive Officer, Director · since 2023

Compensation4.39 M USD
MV

Mr. Mark Verratti

(56)

Chief Operating Officer and Chief Commercial Officer

Compensation3.71 M USD
DM

Dr. Dale Muzzey

(45)

Chief Scientific Officer

Compensation3.01 M USD
KH

Mr. Kevin Haas

(40)

Chief Technology Officer

Compensation1.64 M USD
SP

Ms. S. Louise Phanstiel

(66)

Independent Chairman of the Board

Compensation563,499.00 USD

Myriad Genetics Supply Chain

Myriad Genetics Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
16 companies
#Name1M3M6M1Y2YTrend
1
Progyny
0.43
0.85
0.56
0.75
0.89
2
Abbott Laboratories
Supplier
0.60
0.61
0.72
0.16
0.73
3
Illumina
Supplier
0.23
0.71
0.78
0.89
0.68
4
Johnson & Johnson
Supplier
-0.34
-0.76
-0.68
-0.29
0.68
5
Eli Lilly
Supplier
0.59
-0.24
-0.54
-0.57
0.61
#Name1M3M6M1Y2YTrend
1
Luminex Corporation
Supplier
0.10
-0.42
-0.63
-0.82
—
2
GlaxoSmithKline
Supplier
0.36
-0.69
-0.64
-0.83
-0.25
3
Merck & Co
Supplier
0.50
-0.69
-0.72
-0.50
-0.15
4
AstraZeneca
Supplier
0.45
-0.56
-0.74
-0.61
-0.12
5
Sanofi
Supplier
0.35
-0.61
-0.70
-0.74
-0.07

Frequently asked questions about Myriad Genetics

The business model of Myriad Genetics Inc revolves around providing molecular diagnostic tests and genetic analysis services. As a leading molecular diagnostics company, Myriad Genetics focuses on developing and marketing innovative genetic tests for various medical conditions, including cancer and genetic disorders. With a strong emphasis on research and technology, Myriad Genetics aims to improve patient care and outcomes through personalized medicine. By offering a wide range of genetic testing services, the company strives to empower healthcare providers and individuals with valuable genetic insights, enabling more precise diagnosis, treatment decisions, and proactive healthcare management. Myriad Genetics Inc's business model primarily centers on genetic testing for various medical conditions.

All fundamentals and in-depth analysis of Myriad Genetics

Our stock analysis for Myriad Genetics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Myriad Genetics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Myriad Genetics Stock
Myriad Genetics Revenue→
Myriad Genetics Stock
Myriad Genetics Net Income→
Myriad Genetics Stock
Myriad Genetics P/E→
Myriad Genetics Stock
Myriad Genetics P/S→
Myriad Genetics Stock
Myriad Genetics EBIT→
Myriad Genetics Stock
Myriad Genetics Dividend→
Myriad Genetics Stock
Myriad Genetics Directors Dealings→
Myriad Genetics Stock
Myriad Genetics Stocks→
Myriad Genetics Stock
Myriad Genetics Market capitalization→
Myriad Genetics Stock
Myriad Genetics Debt→
Myriad Genetics Stock
Myriad Genetics Liabilities→
Myriad Genetics Stock
Myriad Genetics Equity→
Myriad Genetics Stock
Myriad Genetics AAQS→
Myriad Genetics Stock
Myriad Genetics Employees→
Myriad Genetics Stock
Myriad Genetics ROE→
Myriad Genetics Stock
Myriad Genetics ROA→
Myriad Genetics Stock
Myriad Genetics ROCE→
Myriad Genetics Stock
Myriad Genetics News→
Myriad Genetics Stock
Myriad Genetics Analyst Price Targets→

Health Stocks

Myung In Pharm CoMyrexisMyungmoon Pharm CoMyomoN G IndustriesMynd.ai,Naba Alsaha Medical Services Company SJSCMycenax BiotechNabriva TherapeuticsMustang BioNagaileben CoMurni Sadar Tbk PTAll Stocks A–Z →